Hemorrhagic fever virus-induced changes in hemostasis and vascular biology

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 5, 2000, Pages 461-483

  Chen, James P ^a,c   Cosgriff, T M ^b  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^b Hematology Oncology Services   (United States)

^c UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

Coagulation factors; Complement; Cytokines; Disseminated intravascular coagulation; Inflammation; Platelets; Vascular dysfunction; Viral hemorrhagic fever; Viral therapy

Indexed keywords

BLOOD CLOTTING FACTOR;

ARENAVIRUS; ARTICLE; BLOOD CLOTTING DISORDER; BUNYAVIRUS; CELLULAR IMMUNITY; DENGUE; FILOVIRIDAE; FLAVIVIRUS; HEMORRHAGIC FEVER; HEMOSTASIS; IMMUNE RESPONSE; INFLAMMATION; LASSA FEVER; PRIORITY JOURNAL; THROMBOCYTE; VASCULAR DISEASE; VIRUS HEMORRHAGIC FEVER; VIRUS TRANSMISSION;

ANIMALS; ARENAVIRIDAE; BLOOD COAGULATION DISORDERS; BLOOD PLATELET DISORDERS; BLOOD VESSELS; BUNYAVIRIDAE; FILOVIRIDAE; FLAVIVIRIDAE; HEMORRHAGIC FEVERS, VIRAL; HEMOSTASIS; HUMANS; IMMUNITY; VASCULAR DISEASES;

EID: 0033860396     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200007000-00010     Document Type: Article

References (241)

1. 1. Mayer CF. Epidemic hemorrhagic fever of the Far East (EHF) or endemic hemorrhagic nephroso-nephritis; morphology and pathogenesis. Lab Invest 1952; 1: 291-311.
2. 2. LeDuc JW. Epidemiology of hemorrhagic fever viruses. Rev Infect Dis 1989; 11 (suppl 4): S730-S735.
3. 3. Lacy MD, Smego RA. Viral hemorrhagic fevers. Adv Pediatr Infect Dis 1996; 12: 21-53.
4. 4. Muhlfelder TW, Niemetz J, Krieutzer D, Beebe D, Ward PA, Rosenfeld SI. C5 chemotatic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest 1979; 63: 147-150.
5. 5. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-4537.
6. 6. Colvin RB, Johnson RA, Mihm MC Jr, Dvorak HF. Role of the clotting system in cell-mediated hypersensitivity. 1. Fibrin deposition in delayed skin reactions in man. J Exp Med 1973; 138: 686-698.
7. 7. Østerud B, Lindahl U, Seljelid R. Macrophages produce blood coagulation factors. FEBS Lett 1980; 120: 41-43.
8. 8. Ashida ER, Johnson AR, Lipsky PE. Human endothelial cell-lymphocyte interaction. Endothelial cells function as accessory cells necessary for mitogen-induced human T lymphocyte activation in vitro. J Clin Invest 1981; 67: 1490-1499.
9. 9. Frame JD, Baldwin JM Jr, Gocke DJ, Troup JM. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 1970; 19: 670-676.
10. 10. Buckley SM, Casals J, Downs WG. Isolation and antigenic characterization of Lassa virus. Nature 1970; 227: 174. [Letter]
11. 11. Childs JE, Peters CJ. Ecology and epidemiology of arenaviruses and their hosts. In: Salvato MS (editor): The Arenaviridae. New York: Plenum Press; 1993. pp. 331-384.
12. 12. Monath TP, Newhouse VF, Kemp GE, Setzer HW, Cacciapuoti A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 1974; 185: 263-265.
13. 13. Holmes GP, McCormick JB, Trock SC, et al. Lassa fever in the United States: investigation of a case and new guidelines for management. N Engl J Med 1990; 323: 1120-1123.
14. 14. Arribalzaga RA. Una nueva enfermedad apidemica a germen desconocido: hipertermia nefrotoxica, leucopenica y enantemica. Dia Medico 1955; 27: 1204-1210.
15. 15. Parodi AS, Greenway DJ, Rugeroi HR, et al. Sobre la etiologia del brote epidemico de Junin. Dia Medico 1958; 30: 2300-2302.
16. 16. Maiztegui JI. Clinical and epidemiological patterns of Argentine haemorrhagic fever. Bull World Health Org 1975; 52: 567-575.
17. 17. Mills JN, Ellis BA, McKee KT Jr, et al. A longitudinal study of Junin virus activity in the rodent reservoir of Argentine hemorrhagic fever. Am J Trop Med Hyg 1992; 47: 749-763.
18. 18. Johnson KM, Wiebenga NH, Mackenzie RB, et al. Virus isolations from human cases of hemorrhagic fever in Bolivia. Proc Soc Exp Biol Med 1965; 118: 113-118.
19. 19. Johnson KM, Kuns ML, Mackenzie RB, Webb PA, Yunker CE. Isolation of Machupo virus from wild rodent Calomys callosus. Am J Trop Med Hyg 1966; 15: 103-106.
20. 20. Mackenzie RB. Epidemiology of Machupo virus infection. I. Pattern of human infection. San Joaquin, Bolivia, 1962-1964. Am J Trop Med Hyg 1965; 14: 808-813.
21. 21. Salas R, de Manzione N, Tesh RB, et al. Venezuelan haemorrhagic fever. Lancet 1991; 338: 1033-1036.
22. 22. Tesh RB, Jahrling PB, Salas R, Shope RE. Description of Guanarito virus (Arenaviridae: Arenavirus), the etiologic agent of Venezuelan hemorrhagic fever. Am J Trop Med Hyg 1994; 50: 452-459.
23. 23. Coimbra TLM, Nassar ES, Burattini MN, et al. New arenavirus isolated in Brazil. Lancet 1994; 343: 391-392.
24. 24. Hjelle B, Jenison SA, Goade DE, Green WB, Feddersen RM, Scott AA. Hantaviruses: clinical, microbiologic, and epidemiologic aspects. Crit Rev Clin Lab Sci 1995; 32: 469-508.
25. 25. Peters CJ, LeDuc JW. Bunyaviridae: Bunyaviruses, phleboviruses, and related viruses. In: Belshe RB (editor): Textbook of human virology 2nd edn. St. Louis, MO: Mosby Year Book; 1991. pp. 571-614.
26. 26. Davies FG, Linthicum KJ, James AD. Rainfall and epizootic Rift Valley fever. Bull World Health Org 1985; 63: 941-943.
27. 27. Burney MI, Ghafoor A, Saleen M, Webb PA, Casals J. Nosocomial outbreak of viral hemorrhagic fever caused by Crimean Hemorrhagic fever-Congo virus in Pakistan, January 1976. Am J Trop Med Hyg 1980; 29: 941-947.
28. 28. Swanepoel R, Shepherd AJ, Leman PA, et al. Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in Southern Africa. Am J Trop Med Hyg 1987; 36: 120-132.
29. 29. Schmaljohn CS, Hasty SE, Dalrymple JM, et al. Antigenic and genetic properties of viruses linked to hemorrhagic fever with renal syndrome. Science 1985; 227: 1041-1044.
30. 30. Lee HW, Lee PW, Johnson KM. Isolation of the etiologic agent of Korean Hemorrhagic fever. J Infect Dis 1978; 137: 298-308.
31. 31. Cosgriff TM. Mechanisms of disease in Hantavirus infection: pathophysiology of hemorrhagic fever with renal syndrome. Rev Infect Dis 1991; 13: 97-107.
32. 32. Gligic A, Dimkovic N, Xiao SY, et al. Belgrade virus: a new Hantavirus causing severe hemorrhagic fever with renal syndrome in Yugoslavia. J Infect Dis 1992; 166: 113-120.
33. 33. Khan AS, Khabbaz RF, Armstrong LR, et al. Hantavirus pulmonary syndrome: the first 100 US cases. J Infect Dis 1996; 173: 1297-1303.
34. 34. Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis 1997; 3: 95-104.
35. 35. Peters CJ, Simpson GL, Levy H. Spectrum of Hantavirus infection: hemorrhagic fever with renal syndrome and Hantavirus pulmonary syndrome. Annu Rev Med 1999; 50: 531-545.
36. 36. LeGuenno B, Galabru J. Ebola virus. Bull Inst Pasteur 1997; 95: 73-83.
37. 37. Johnson KM, Lange JV, Webb PA, Murphy FA. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 1977; 1: 569-571.
38. 38. Martini GA, Siegert R (editors). Marburg virus disease. New York: Springer-Verlag; 1971.
39. 39. Khan AS, Sanchez A, Pflieger AK. Filoviral haemorrhagic fevers. Br Med Bull 1998; 54: 675-692.
40. 40. Gear JH. Clinical aspects of African viral hemorrhagic fevers. Rev Infect Dis 1989; 11 (suppl 4): S777-S782.
41. 41. Leirs H, Mills JN, Krebs JW, et al., study group members. Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. J Infect Dis 1999; 179 (suppl 1): S155-S163.
42. 42. Sinniah M, Igarashi A. Dengue haemorrhagic fever. Med Virol 1995; 5: 193-203.
43. 43. Nimmannitya S, Halstead SB, Cohen SN, Margiotta MR. Dengue and chikungunya virus infection in man in Thailand, 1962-1964. I. Observations on hospitalized patients with hemorrhagic fever. Am J Trop Med Hyg 1969; 18: 954-971.
44. 44. Halstead SB, Nimmannitya S, Margiotta MR. Dengue and chikungunya virus infection in man in Thailand, 1962-1964. II. Observations on disease in outpatients. Am J Trop Med Hyg 1969; 18: 972-983.
45. 45. Khin MM, Than KA. Transovarial transmission of dengue 2 virus by Aedes aegypti in nature. Am J Trop Med Hyg 1983; 32: 590-594.
46. 46. Fan W, Yu S, Cosgriff TM. The reemergence of dengue in China. Rev Infect Dis 1989; 11 (suppl 4): S847-S853.
47. 47. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42: 179-184.
48. 48. Halstead SB. The pathogenesis of dengue. Molecular epidemiology in infectious disease. Am J Epidemiol 1981; 114: 632-648.
49. 49. Monath TP, Heinz FX. Flaviviruses. In: Fields BN, Knipe DM, Howley PM, et al. (editors): Fields virology. Philadelphia, PA: Lippincott-Raven Publishers; 1996. pp. 961-1034.
50. 50. Robertson SE, Hull BP, Tomori O, Bele O, LeDuc JW, Estenes K. Yellow-fever: a decade of reemergence. JAMA 1996; 276: 1157-1162.
51. 51. McFarland JM, Baddour LM, Nelson JE, et al. Imported yellow fever in a United States citizen. Clin Infect Dis 1997; 25: 1143-1147.
52. 52. Pavri K. Clinical, clinicopathologic, and hematologic features of Kyasanur Forest disease. Rev Infect Dis 1989; 11 (suppl 4): S854-S859.
53. 53. Bierman HR, Nelson ER. Hematodepressive virus diseases of Thailand. Ann Intern Med 1965; 62: 867-884.
54. 54. Na-Nakorn S, Suingdumrong A, Pootrakul S, Bhamarapravati N. Bone-marrow studies in Thai haemorrhagic fever. Bull World Health Org 1966; 35: 54-55.
55. 55. Mitrakul C, Poshyachinda M, Futrakul P, Sangkawibba N, Ahandrik S. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg 1977; 26: 975-984.
56. 56. La Russa VF, Innis BL. Mechanisms of dengue virus-induced bone marrow suppression. Baillieres Clin Haematol 1995; 8: 249-270.
57. 57. Park S, Kim BK, Lee JS, Lee M. A study on thrombokinetics in Korean hemorrhagic fever. Seoul J Med 1986; 26: 69-80.
58. 58. Lee M, Park S, Chang YB, et al. Electron microscopic features of bone marrow cells in Korean hemorrhagic fever. Seoul J Med 1986; 27: 233-244.
59. 59. Carballal G, Cossio PM, Laguens RP, et al. Junin virus infection of guinea pigs: immunohistochemical and ultrastructural studies of hemopoietic tissue. J Infect Dis 1981; 143: 7-14.
60. 60. deBracco MM, Rimoldi MT, Cossio PM, et al. Argentine hemorrhagic fever. Alterations of the complement system and anti-Junin-virus humoral response. N Engl J Med 1978; 299: 216-221.
61. 61. Lange JV, Mitchell SW, McCormick JB, Walker DH, Evatt BL, Ramsey RR. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am J Trop Med Hyg 1985; 34: 999-1007.
62. 62. Al-Tikriti SK, Al-Ani F, Jurji FJ, et al. Congo-Crimean haemorrhagic fever in Iraq. Bull World Health Org 1981; 59: 85-90.
63. 63. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 11 (suppl 4): S794-S800.
64. 64. Lee M, Kim BK, Kim S, et al. Coagulopathy in hemorrhagic fever with renal syndrome (Korean hemorrhagic fever). Rev Infect Dis 1989; 11 (suppl 4): S877-S883.
65. 65. Guang MY, Liu GZ, Cosgriff TM. Hemorrhage in hemorrhagic fever with renal syndrome in China. Rev Infect Dis 1989; 11 (suppl 4): S884-S890.
66. 66. Bhamarapravati N. Hemostatic defects in dengue hemorrhagic fever. Rev Infect Dis 1989; 11 (suppl 4): S826-S829.
67. 67. Kautner I, Robinson MJ, Kuhnle U. Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention. J Pediatr 1997; 131: 516-524.
68. 68. Gear JS, Cassel GA, Gear AJ, et al. Outbreak of Marburg virus disease in Johannesburg. Br Med J 1975; 4: 489-493.
69. 69. Shulman NR, Jordan JV Jr. Platelet immunology. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (editors): Hemostasis and thrombosis: basic principles and clinical practice 2nd edn. Philadelphia, PA: JB Lippincott; 1987. pp. 452-529.
70. 70. Boonpucknavig S, Vuttiviroj O, Bunnag C, Bhamarapravati N, Nimmannitya S. Demonstration of dengue antibody complexes on the surface of platelets from patients with dengue hemorrhage fever. Am J Trop Med Hyg 1979; 28: 881-884.
71. 71. Cosgriff TM. Viruses and hemostasis. Rev Infect Dis 1989; 11 (suppl 4): S672-S688.
72. 72. Marder VJ. Consumptive thrombohemorrahgic disorders. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA (editors): Hematology 3rd edn. New York: McGraw-Hill; 1983. pp. 1433-1461.
73. 73. Jerushalmy Z, Zucker MB. Some effects of fibrinogen degradation products (FDP) on blood platelets. Thromb Diath Haemorrh 1966; 15: 413-419.
74. 74. Kowalski E. Fibrinogen derivatives and their biologic activities. Semin Hematol 1968; 5: 45-59.
75. 75. Pareti FI, Capitanio A, Mannucci PM. Acquired storage pool disease in platelets during disseminated intravascular coagulation. Blood 1976; 48: 511-515.
76. 76. Rabiner SF. Uremic bleeding. Prog Hemost Thromb 1972; 1: 233-250.
77. 77. Cummins D, Fisher-Hoch SP, Walshe KJ, et al. A plasma inhibitor of platelet aggregation in patients with Lassa fever. Br J Haematol 1989; 72: 543-548.
78. 78. Cummins D, Molinas FC, Lerer G, Maiztegui JI, Faint R, Machin SJ. A plasma inhibitor of platelet aggregation in patients with Argentine hemorrhagic fever. Am J Trop Med Hyg 1990; 42: 470-475.
79. 79. Marta RF, Heller MV, Maiztegui JI, Molinas FC. Further studies on the plasma inhibitor of platelet activation in Argentine hemorrhagic fever. Thromb Haemost 1993; 69: 526-527.
80. 80. Cosgriff TM, Lee HW, See AF, et al. Platelet dysfunction contributes to the haemostatic defect in haemorrhagic fever with renal syndrome. Trans R Soc Trop Med Hyg 1991; 85: 660-663.
81. 81. Comp PC. Production of coagulation factors. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA (editors): Hematology 4th edn. New York: McGraw-Hill; 1990. pp. 1285-1290.
82. 82. Elton NW, Romero A, Trejos A. Clinical pathology of yellow fever. Am J Clin Pathol 1955; 25: 135-146.
83. 83. Dennis LH, Reisberg BE, Crosbie J, Crozier D, Conrad ME. The original haemorrhagic fever: yellow fever. Br J Haematol 1969; 17: 455-462.
84. 84. Cosgriff TM, Parrish DB, Jahrling PB, Huggins JW, Lewis RM, Peters CJ. The original hemorrhagic fever revisited: hemostatic derangement in rhesus monkeys infected with yellow fever virus. Blood 1987; 70: 369A. [Abstract]
85. 85. Deubel V, Huerre M, Cathomas G, et al. Molecular detection and characterization of yellow fever virus in blood and liver specimens of a non-vaccinated fatal human case. J Med Virol 1997; 53: 212-217.
86. 86. Ishak KG, Walker DH, Coetzer JA, Gardner JJ, Gorelkin L. Viral hemorrhagic fevers with hepatic involvement: pathologic aspects with clinical correlations. Prog Liver Dis 1982; 7: 495-515.
87. 87. Abdel-Wahab KS, El Baz LM, El-Tayeb EM, Omar H, Ossman MA, Yasin W. Rift Valley Fever virus infections in Egypt: pathological and virological findings in man. Trans R Soc Trop Med Hyg 1978; 72: 392-396.
88. 88. Cosgriff TM, Morrill JC, Jennings GB, et al. Hemostatic derangement produced by Rift Valley fever virus in rhesus monkeys. Rev Infect Dis 1989; 11 (suppl 4): S807-S814.
89. 89. McKay DG, Margaretten W. Disseminated intravascular coagulation in virus diseases. Arch Intern Med 1967; 120: 129-152.
90. 90. Srichaikul T, Nimmannitya S, Artchararit N, Siriasawakul T, Sungpeuk P. Fibrinogen metabolism and disseminated intravascular coagulation in dengue hemorrhagic fever. Am J Trop Med Hyg 1977; 26: 525-532.
91. 91. Burt FJ, Swanepoel R, Shieh WJ, et al. Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med 1997; 121: 839-846.
92. 92. Fisher-Hoch SP, Platt GS, Neild GH, et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 1985; 152: 887-894.
93. 93. Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, Topper M, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120: 140-155.
94. 94. Molinas FC, de Bracco MM, Maiztegui JI. Coagulation studies in Argentine hemorrhagic fever. J Infect Dis 1981; 143: 1-6.
95. 95. Elsner B, Schwarz E, Mando OG, Maiztegui J, Vilches A. Pathology of 12 fatal cases of Argentine hemorrhagic fever. Am J Trop Med Hyg 1973; 22: 229-236.
96. 96. Heller MV, Marta RF, Sturk A, Maiztegui JI, Hack CE, Cate JW, et al. Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever. Thromb Haemost 1995; 73: 368-373.
97. 97. Knobloch J, McCormick JB, Webb PA, Dietrich M, Schumacher HH, Dennis E. Clinical observations in 42 patients with Lassa fever. Tropenmed Parasitol 1980; 31: 389-398.
98. 98. Fisher-Hoch SP, Mitchell SW, Sasso DR, Lange JV, Ramsey R, McCormick JB. Physiologic and immunologic disturbances associated with shock in a primate model of Lassa fever. J Infect Dis 1987; 155: 465-474.
99. 99. Fisher-Hoch S, McCormick JB, Sasso D, Craven RB. Hematologic dysfunction in Lassa fever. J Med Virol 1988; 26: 127-135.
100. 100. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989; 11 (suppl 4): S830-S839.
101. 101. Kurane I, Rothman AL, Livingston PG, et al. Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome. Arch Virol Suppl 1994; 9: 59-64.
102. 102. Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977; 146: 201-217.
103. 103. Halstead SB, O'Rourke EJ, Allison AC. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med 1977; 146: 218-229.
104. 104. Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol 1997; 71: 4226-4232.
105. 105. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427-451.
106. 106. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618-623.
107. 107. Bokisch VA, Top FH Jr, Russell PK, Dixon FJ, Müller-Eberhard HJ. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med 1973; 289: 996-1000.
108. 108. Pathogenetic mechanisms in dengue haemorrhagic fever: report of an international collaborative study. Bull World Health Org 1973; 48: 117-133.
109. 109. Ruangjirachuporn W, Boonpucknavig S, Nimmannitya S. Circulating immune complexes in serum from patients with dengue haemorrhagic fever. Clin Exp Immunol 1979; 36: 46-53.
110. 110. Boonpucknavig S, Boonpucknavig V, Bhamarapravati N, Nimmannitya S. Immunofluorescence study of skin rash in patients with dengue hemorrhagic fever. Arch Pathol Lab Med 1979; 103: 463-466.
111. 111. Sheedy JA, Froab HF, Batson HA, et al. Sumposium on epidemic hemorrhagic fever; clinical course of epidemic hemorrhagic fever. Am J Med 1954; 16: 619-628.
112. 112. Lukes RJ. Symposium on epidemic hemorrhagic fever; pathology of thirty-nine fatal cases of epidemic hemorrhagic fever. Am J Med 1954; 16: 639-650.
113. 113. Cosgriff TM, Lewis RM. Mechanisms of disease in hemorrhagic fever with renal syndrome. Kidney Int 1991; 40 (suppl): S72-S79.
114. 114. Nolte KB, Feddersen RM, Foucar K, et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum Pathol 1995; 26: 110-120.
115. 115. Joubert JR, King JB, Rossouw DJ, Cooper R. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part III. Clinical pathology and pathogenesis. S Afr Med J 1985; 68: 722-728.
116. 116. Child PL, MacKenzie RB, Valverde LR, Johnson KM. Bolivian hemorrhagic fever: a pathologic description. Arch Pathol 1967; 83: 434-445.
117. 117. Walker DH, McCormick JB, Johnson KM, et al. Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 1982; 107: 349-356.
118. 118. Baskerville A, Fisher-Hoch SP, Neild GH, Dowsett AB. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol 1985; 147: 199-209.
119. 119. The Subcommittee on Arbovirus Laboratory Safety of the American Committee on Arthropod-Borne Viruses. Laboratory safety for arboviruses and certain other viruses of vertebrates. Am J Trop Med Hyg 1980; 29: 1359-1381.
120. 120. Jahrling PB, Hesse RA, Rhoderick JB, Elwell MA, Moe JB. Pathogenesis of a Pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect Immun 1981; 32: 872-880.
121. 121. Trapido H, Sanmartin C. Pichinde virus, a new virus of the Tacaribe group from Colombia. Am J Trop Med Hyg 1971; 20: 631-641.
122. 122. Liu CT, Jahrling PB, Peters CJ. Evidence for the involvement of sulfidopeptide leukotrienes in the pathogenesis of Pichinde virus infection in strain 13 guinea pigs. Prostaglandins Leukot Med 1986; 24: 129-138.
123. 123. Qian C, Jahrling PB, Peters CJ, Liu CT. Cardiovascular and pulmonary responses to Pichinde virus infection in strain 13 guinea pigs. Lab Anim Sci 1994; 44: 600-607.
124. 124. Schaeffer RC Jr, Bitrick MS Jr, Connolly B, Jenson AB, Gong F. Pichinde virus-induced respiratory failure due to obstruction of the small airways: structure and function. Exp Lung Res 1993; 19: 715-729.
125. 125. Lucia HL, Coppenhaver DH, Harrison RL, Baron S. The effect of an arenavirus infection on liver morphology and function. Am J Trop Med Hyg 1990; 43: 93-98.
126. 126. Cosgriff TM, Jahrling PB, Chen JP, et al. Studies of the coagulation system in arenaviral hemorrhagic fever: experimental infection of strain 13 guinea pigs with Pichinde virus. Am J Trop Med Hyg 1987; 36: 416-423.
127. 127. Chen JP, Marsh LC, Schroeder EC. Haemostatic derangements associated with arenavirus infection in the guinea-pig: radioimmunoassay of fibrinopeptide A to assess thrombin action in infected animals. Blood Coag Fibrinol 1993; 4: 165-172.
128. 128. Aronson JF, Herzog NK, Jerrells TR. Tumor necrosis factor and the pathogenesis of Pichinde virus infection in guinea pigs. Am J Trop Med Hyg 1995; 52: 262-269.
129. 129. Molinas FC, Paz RA, Rimoldi MT, de Bracco MM. Studies of blood coagulation and pathology in experimental infection of guinea pigs with Junin virus. J Infect Dis 1978; 137: 740-746.
130. 130. Rimoldi MT, de Bracco MM. In vitro inactivation of complement by a serum factor present in Junin-virus infected guinea-pigs. Immunology 1980; 39: 159-164.
131. 131. Oubina JR, Carballal G, Videla CM, Cossio PM. The guinea pig model for Argentine hemorrhagic fever. Am J Trop Med Hyg 1984; 33: 1251-1257.
132. 132. Molinas FC, Giavedoni E, Frigerio MJ, Calello MA, Barcat JA, Weissenbacher MC. Alteration of blood coagulation and complement system in neotropical primates infected with Junin virus. J Med Virol 1983; 12: 281-292.
133. 133. Molinas FC, de Bracco MM, Maiztegui JI. Hemostasis and the complement system in Argentine hemorrhagic fever. Rev Infect Dis 1989; 11 (suppl 4): S762-S770.
134. 134. Callis RT, Jahrling PB, DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am J Trop Med Hyg 1982; 31: 1038-1045.
135. 135. Walker DH, Johnson KM, Lange JV, Gardner JJ, Kiley MP, McCormick JB. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J Infect Dis 1982; 146: 360-368.
136. 136. Kastello MD, Eddy GA, Kuehne RW. A rhesus monkey model for the study of Bolivian hemorrhagic fever. J Infect Dis 1976; 133: 57-62.
137. 137. Scott SK, Hickman RL, Lang CM, Eddy GA, Hilmas DE, Spertzel RO. Studies of the coagulation system and blood pressure during experimental Bolivian hemorrhagic fever in rhesus monkeys. Am J Trop Med Hyg 1978; 27: 1232-1239.
138. 138. Hall WC, Geisbert TW, Huggins JW, Jahrling PB. Experimental infection of guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of human disease. Am J Trop Med Hyg 1996; 55: 81-88.
139. 139. Anderson GW Jr, Slone TW Jr, Peters CJ. Pathogenesis of Rift Valley fever virus (RVFV) infection in inbred rats. Microb Pathogen 1987; 2: 283-293.
140. 140. Morrill JC, Jennings GB, Johnson AJ, Cosgriff T, Gibbs PH, Peters CJ. Pathogeneis of Rift Valley fever virus in rhesus monkeys: role of interferon response. Arch Virol 1990; 110: 195-212.
141. 141. Kim GR, McKee KT. Pathogenesis of Hantaan virus infection in suckling mice: clinical, virologic, and serologic observations. Am J Trop Med Hyg 1985; 34: 388-395.
142. 142. Groen J, Gerding M, Koeman JP, et al. A macaque model for Hantavirus infection. J Infect Dis 1995; 172: 38-44.
143. 143. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. The pathology of experimental Ebola virus infection in monkeys. J Pathol 1978; 125: 131-138.
144. 144. Ryabchikova EI, Kolesnibkova LV, Netesov SV. Animal pathology of Filoviral infections. Curr Top Microbiol Immunol 1999; 235: 145-173.
145. 145. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179 (suppl 1): S230-S217.
146. 146. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178: 651-661.
147. 147. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 1973; 128: 7-14.
148. 148. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 1973; 128: 15-22.
149. 149. Wu SJ, Hayes CG, Dubois DR, et al. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am J Trop Med Hyg 1995; 52: 468-476.
150. 150. Bearcroft WG. The histopathology of the liver of yellow fever-infected rhesus monkeys. J Pathol Bacteriol 1957; 74: 295-303.
151. 151. Tigertt WD, Berge TO, Gochenour WS, et al. Experimental yellow fever. Trans N Y Acad Sci 1960; 22: 323-333.
152. 152. Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg 1981; 30: 431-443.
153. 153. Andrews BS, Theofilopoulos AN, Peters CJ, Loskutoff DJ, Brandt WE, Dixon FJ. Replication of dengue and junin viruses in cultured rabbit and human endothelial cells. Infect Immun 1978; 20: 776-781.
154. 154. Lewis RM, Johnson ED, Jahrling PB, Edgell C-J, Cosgriff TM, Peters CJ. In vitro infection of endothelial cells by Ebola, Lassa, and Marburg viruses. Abstracts of the 85th Annual Meeting of the American Society of Microbiology, Las Vegas, NV; March 1985. p. 295.
155. 155. Peters CJ, Liu CT, Anderson GW Jr, Morrill JC, Jahrling PB. Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted. Rev Infect Dis 1989; 11 (suppl 4): S743-S749.
156. 156. Pensiero MN, Sharefkin JB, Dieffenbach CW, Hay J. Hantaan virus infection of human endothelial cells. J Virol 1992; 66: 5929-5936.
157. 157. Yanagihara B, Silverman DJ. Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses. Arch Pathol 1990; 111: 281-286.
158. 158. Schnittler JH, Mahner F, Drenckhahn D, Klenk HD, Feldmann H. Replication of Marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic diseae. J Clin Invest 1993; 91: 1301-1309.
159. 159. Hung T, Zhou JY, Tang YM, Zhao TX, Baek LJ, Lee HW. Identification of Hantaan virus-related structures in kidneys of cadavers with haemorrhagic fever and renal syndorme. Arch Virol 1992; 122: 187-199.
160. 160. Geisbert TW, Jahrling PB, Hanes MA, Zack PM. Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol 1992; 106: 137-152.
161. 161. Zaki SR, Greer PW, Coffield LM, et al. Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease. Am J Pathol 1995; 146: 552-579.
162. 3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA 1998; 95: 7074-7079.
163. 163. Nagai T, Tanishita O, Takahashi Y, et al. Isolation of haemorrhagic fever with renal syndrome virus from leukocytes of rats and virus replication in cultures of rat and human macrophages. J Gen Virol 1985; 66: 1271-1278.
164. 164. Yang Z, Delgado R, Xu L, et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 1998; 279: 1034-1037.
165. 165. Maruyama T, Buchmeier MJ, Parren PWHI, Burton DR. Ebola virus, neutrophils,and antibody specificity. Science 1998; 282: 843a. [Letter]
166. 166. Maiztegui JI, Laguens RP, Cossi PM, et al. Ultrastructural and immunohistochemical studies in five cases of Argentine hemorrhagic fever. J Infect Dis 1975; 132: 35-53.
167. 167. Peters CJ, Jones D, Trotter R, et al. Experimental Rift Valley fever in rhesus macaques. Arch Virol 1988; 99: 31-44.
168. 168. Peters CJ, Sanchez A, Rollin PE, Ksiazek TG, Murphy FA. Filoviridae: Marburg and Ebola viruses. In: Fields BN, Knipe DM, Howley PM, et al. (editors): Fields virology. Philadelphia, PA: Lippincott-Raven Press Publishers; 1996. pp. 1161-1176.
169. 169. Cummins D. Arenaviral haemorrhagic fevers. Blood Rev 1991; 5: 129-137.
170. 170. Laguens M, Chambo JG, Laguens RP. In vivo replication of pathogenic and attenuated strains of Junin virus in different cell populations of lymphatic tissue. Infect Immun 1983; 41: 1279-1283.
171. 171. Lewis RM, Morrill JC, Jahrling PB, Cosgriff TM. Replication of hemorrhagic fever viruses in monocytic cells. Rev Infect Dis 1989; 11 (suppl 4): S736-S742.
172. 172. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. Filovirus-induced endothelial leakage triggered by infected monocytes/ macrophages. J Virol 1996; 70: 2208-2214.
173. 173. Liprandi F, Walder R. Replication of virulent and attenuated strains of yellow fever virus in human monocyte and macrophage-like cells (U937). Arch Virol 1983; 76: 51-61.
174. 174. Ambrosio AM, Enria DA, Maiztegui JI. Junin virus isolation from lympho-mononuclear cells of patients with Argentine hemorrhagic fever. Intervirology 1986; 25: 97-102.
175. 175. Yao ZO, Yang WS, Zhang WB, Bai XF. The distribution and duration of Hantaan virus in the body fluids of patients with hemorrhagic fever with renal syndrome. J Infect Dis 1989; 160: 218-224.
176. 176. Ryabchikova E, Strelets L, Kolesnikova L, Pyankov O, Sergeev A. Respiratory Marburg virus infection in guinea pigs. Arch Virol 1996; 141: 2177-2190.
177. 177. Connolly BM, Jenson AB, Peters CJ, Geyer SJ, Barth JF, McPherson RA. Pathogenesis of Pichinde virus infection in strain 13 guinea pigs: an immunocytochemical, virologic, and clinical chemistry study. Am J Trop Med Hyg 1993; 49: 10-24.
178. 178. Morahan PS, Connor JR, Leary KR. Viruses and the versatile macrophage. Br Med Bull 1985; 41: 15-21.
179. 179. Shepherd AJ, Swanepoel R, Leman PA. Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11 (suppl 4): S801-S806.
180. 180. Feldmann H, Klenk HD. Marburg and Ebola viruses. Adv Virus Res 1996; 47: 1-52.
181. 181. Vaporciyan AA, Ward PA. The inflammatory response. In: Beutler E, Lichtman MA, Coller BA, Kipps TJ (editors): Williams Hematology 5th edn. New York: McGraw-Hill; 1995. pp. 48-57.
182. 182. Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemic cell line U937 and peripheral blood monocytes. Blood 1988; 72: 128-133.
183. 183. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745.
184. 184. Remick DG, Kunkel SL. Pathophysiologic alterations induced by tumor necrosis factor. Int Rev Exp Pathol 1993; 34B: 7-25.
185. 185. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460-3464.
186. 186. Isner JM, Dietz WA. Cardiovascular consequences of recombinant DNA technology. Interleukin-2. Ann Intern Med 1988; 109: 933-935.
187. 187. Levis SC, Saavedra MC, Ceccoli C, et al. Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. J Interferon Res 1985; 5: 383-389.
188. 188. Heller MV, Saavedra MC, Fulcoff R, Maiztegui JI, Molinas FC. Increased tumor necrosis factor-α levels in Argentine hemorrhagic fever. J Infect Dis 1992; 166: 1203-1204.
189. 189. Morrill JC, Jenning GB, Cosgriff TM, Gibbs PH, Peters CJ. Prevention of Rift Valley fever in rhesus monkeys with interferon-α. Rev Infect Dis 1989; 11 (suppl 4): S815-S825.
190. 190. Settergren B, Ahlm C, Alexeyev O, Billheden J, Stegmayr B. Pathogenetic and clinical aspects of the renal involvement in hemorrhagic fever with renal syndrome. Ren Fail 1997; 19: 1-14.
191. 191. Lewis RM, Lee HW, See AF, et al. Changes in populations of immune effector cells during the course of haemorrhagic fever with renal syndrome. Trans R Soc Trop Med Hyg 1991; 85: 282-286.
192. 192. Lee JH, Kim GH, Kim YG. The changes of peripheral lymphocyte subsets in Korean hemorrhagic fever. Kor J Nephrol 1992; 11: 343-357.
193. 193. Wang JR, Yang PZ, Wu Q, Sunt T, Xu ZY, Dai ZY. The role of tissue immune complex, complement activation and its immunopathologic injury in the pathogenesis of epidemic hemorrhagic fever. Chin Med J (Engl) 1986; 99: 21-26.
194. 194. Gu XS, Wang DQ, Yang SH, Yan DY. Activation of the alternative complement pathway in patients with epidemic hemorrhagic fever. Chin Med J (Engl) 1984; 97: 283-290.
195. 195. Theofilopoulos AN, Dixon FJ. Immune complexes in human diseases. Am J Pathol 1980; 100: 530-591.
196. 196. Morgan EL, Ember JA, Sanderson SD, et al. Anti-C5a receptor antibodies: characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted animo-terminal sequence of the human C5a receptor. J Immunol 1993; 151: 377-388.
197. 197. Baldwin WM III, Pruitt SK, Brauer RB, Daha MR, Sanfilippo F. Complement in organ transplantation. Contribution to inflammation, injury, and rejection. Transplantation 1995; 59: 797-808.
198. 198. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77: 394-398.
199. 199. Linderholm M, Ahlm C, Settergren B, Waage A, Tarnvik A. Elevated plasma levels of tumor necrosis factor (TNF)-α, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. J Infect Dis 1996; 173: 38-43.
200. 200. Yang CW, Bang BK. Changes in serum levels of tumor necrosis factor-alpha in patients with hemorrhagic fever with renal syndrome. J Catholic Med Coll 1992; 45: 819-830.
201. 201. Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. JAMA 1994; 271: 226-233.
202. 202. Bull BS, Bull MH. Hypothesis: disseminated intravascular inflammation as the inflammatory counterpart to disseminated intravascular coagulation. Proc Natl Acad Sci USA 1994; 91: 8190-8194.
203. 203. Demling RH. The modern version of adult respiratory distress syndrome. Annu Rev Med 1995; 46: 193-202.
204. 204. Hasegawa N, Husari AW, Hart WT, Kandra TG, Raffin TA. Role of the coagulation system in ARDS. Chest 1994; 105: 268-277.
205. 205. Mori M, Rothman AL, Kurane I, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal Hantavirus pulmonary syndrome. J Infect Dis 1999; 179: 295-302.
206. 206. Bustamante EA, Levy H, Simpson SQ. Pleural fluid characteristics in hantavirus pulmonary syndrome. Chest 1997; 112: 1133-1136.
207. 207. Hallin GW, Simpson SQ, Crowell RE, James DS, Koster FT, Mertz GJ, et al. Cardiopulmonary manifestations of Hantavirus pulmonary syndrome. Crit Care Med 1996; 24: 252-258.
208. 208. Linderholm M, Sandstrom T, Rinnstrom O, Groth S, Blomberg A, Tarnvik A. Impaired pulmonary function in patients with hemorrhagic fever with renal syndrome. Clin Infect Dis 1997; 25: 1084-1089.
209. 209. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
210. 210. Marrack P, Kappler J. Subversion of the immune system by pathogens. Cell 1994; 76: 323-332.
211. 211. Xiao SY, Zhu B, Zhang M, Zhang T, Zheng Z, Xiang J. A sequential study of serum specific IgM antibody responses in patients with epidemic hemorrhagic fever and its relationship to the severity of illness. Chin J Immunol 1986; 4: 218-221.
212. 212. Villinger F, Rollin PE, Brar SS, et al. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J Infect Dis 1999; 179 (suppl 1): S188-S191.
213. 213. Schnittler HJ, Feldmann H. Molecular pathogenesis of Filovirus infections: role of macrophages and endothelial cells. Curr Top Microbiol Immunol 1999; 235: 175-204.
214. 214. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. Filovirus-induced endothelial leakage triggered by infected monocytes/ macrophages. J Virol 1996; 70: 2208-2214.
215. 215. Kurane I, Innis BL, Nimmannitya S, et al. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-γ in sera of children with dengue. J Clin Invest 1991; 88: 1473-1480.
216. 216. Boonpucknavig V, Bhamarapravati N, Boonpucknavig S, Futrakul P, Tanpaichitr P. Glomerular changes in dengue haemorrhagic fever. Arch Pathol Lab Med 1976; 100: 206-212.
217. 217. Yadav M, Kamath KR, Iyngkaran N, Sinniah M. Dengue hemorrhagic fever and dengue shock syndrome: are they tumor necrosis factor-mediated disorders? FEMS Microbiol Immunol 1991; 4: 45-49.
218. 218. Hober D, Poli L, Roblin B, et al. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 β (IL-1 β) in dengue-infected patients. Am J Trop Med Hyg 1993; 48: 324-331.
219. 219. Lee DH, Tam SS, Benyoucef S, DeGroote D, Deubel V, Wattre P. Enhanced TNF-α production by monocytic-like cells exposed to dengue virus antigens. Immunol Lett 1996; 53: 115-120.
220. 220. Bethell DB, Flobbe K, Cao XT, et al. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis 1998; 177: 778-782.
221. 221. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
222. 222. Levy G, Abecassis M. Activation of the immune coagulation system by murine hepatitis virus strain 3. Rev Infect Dis 1989; 11 (suppl 4): S712-S721.
223. 223. Peters CJ, Johnson KM. Hemorrhagic fever viruses. In: Notkins AL, Oldstone MBA (editors): Concepts in viral pathogenesis. New York: Springer-Verlag; 1984. pp. 325-337.
224. 224. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. Lancet 1988; 297: 584-587.
225. 225. Huggins JW. RNA viruses that cause hemorrhagic, encephalitic, and febrile disease. In: Galasso GJ, Whitley RJ, Merigan TC (editors): Antiviral agents and viral diseases of man 3rd edn. New York: Raven Press; 1990. pp. 691-726.
226. 226. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11 (suppl 4): S750-S761.
227. 227. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314: 20-26.
228. 228. Fisher-Hoch SP, Gborie S, Parker L, Huggins J. Unexpected adverse reactions during a clinical trial in rural West Africa. Antiviral Res 1992; 19: 139-147.
229. 229. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164: 1119-1127.
230. 230. Yang ZQ, Zhang TM, Zhang MV, et al. Interruption study of viremia of patients with hemorrhagic fever with renal syndrome in the febrile phase. Chin Med J (Engl) 1991; 104: 149-153.
231. 231. Andrei G, DeClercq E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res 1993; 22: 45-75.
232. 232. Stephenson JR. Flavivirus vaccines. Vaccine 1988; 6: 471-480.
233. 233. Kurane I, Ennis FE. Immunity and immunopathology in dengue virus infections. Semin Immunol 1992; 4: 121-127.
234. 234. Bhamarapravati N, Yoksan S. The clinical trial of trivalent dengue vaccine. Southeast Asian J Trop Med Publ Hlth 1990; 21: 709. [Abstract]
235. 235. Lai CJ, Bray M, Men R, et al. Evaluation of molecular strategies to develop a live dengue vaccine. Clin Diagn Virol 1998; 10: 173-179.
236. 236. Maiztegui JI, McKee KT Jr, Barrera Oro JG, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF study group. J Infect Dis 1998; 177: 277-283.
237. 237. Maruyama T, Parren PW, Sanchez A, et al. Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 1999; 179 (suppl 1): S235-S239.
238. 238. Maruyama T, Rodriguez LL, Jahrling PB, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 1999; 73: 6024-6030.
239. 239. Centers for Disease Control and Prevention. Addressing emerging infectious disease threats: a prevention strategy for the United States. Atlanta, GA: Centers for Disease Control and Prevention; 1994.
240. 240. Sable CA, Mandell GL. The role of molecular techniques in the understanding of emerging infections. Mol Med Today 1996; 2: 120-128.
241. 241. Nichol ST, Spiropoulou CF, Morzunov S, et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 1993; 262: 914-917.